Repligen (NASDAQ:RGEN) Stock Unloaded Rep. Lisa C. McClain

Representative Lisa C. McClain (R-Michigan) recently sold shares of Repligen Corporation (NASDAQ:RGEN). In a filing disclosed on November 21st, the Representative disclosed that they had sold between $1,001 and $15,000 in Repligen stock on October 31st. The trade occurred in the Representative’s “CHARLES SCHWAB 401K > SCHWAB 893” account.

Representative Lisa C. McClain also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Alibaba Group (NYSE:BABA) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Coherent (NYSE:COHR) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Clorox (NYSE:CLX) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Northern Trust (NASDAQ:NTRS) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Honda Motor (NYSE:HMC) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Home BancShares (NYSE:HOMB) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Five Below (NASDAQ:FIVE) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Pure Storage (NYSE:PSTG) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of BHP Group (NYSE:BHP) on 10/31/2025.

Repligen Stock Performance

Shares of NASDAQ RGEN traded down $0.58 during trading hours on Wednesday, hitting $171.18. 498,847 shares of the stock were exchanged, compared to its average volume of 823,434. Repligen Corporation has a one year low of $102.96 and a one year high of $182.52. The company’s 50 day moving average is $147.81 and its 200 day moving average is $131.23. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.59 and a quick ratio of 7.32. The firm has a market capitalization of $9.64 billion, a P/E ratio of 8,563.28, a P/E/G ratio of 3.32 and a beta of 1.15.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Tuesday, October 28th. The biotechnology company reported $0.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.42 by $0.04. The company had revenue of $188.81 million during the quarter, compared to analysts’ expectations of $181.23 million. Repligen had a net margin of 0.25% and a return on equity of 4.70%. The business’s quarterly revenue was up 21.9% compared to the same quarter last year. During the same period in the prior year, the company earned $0.43 earnings per share. Repligen has set its FY 2025 guidance at 1.650-1.680 EPS. On average, research analysts expect that Repligen Corporation will post 1.72 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. Wall Street Zen cut Repligen from a “buy” rating to a “hold” rating in a research report on Tuesday, November 4th. Canaccord Genuity Group raised their price target on shares of Repligen from $150.00 to $165.00 and gave the stock a “hold” rating in a research report on Wednesday, October 29th. Barclays increased their target price on shares of Repligen from $160.00 to $175.00 and gave the company an “overweight” rating in a research note on Wednesday, October 29th. Weiss Ratings restated a “sell (d+)” rating on shares of Repligen in a research note on Tuesday. Finally, Evercore ISI lifted their price objective on Repligen from $155.00 to $175.00 and gave the stock an “outperform” rating in a report on Tuesday, October 7th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Repligen has a consensus rating of “Moderate Buy” and an average price target of $173.85.

Insider Buying and Selling at Repligen

In related news, Director Anthony Hunt sold 25,000 shares of Repligen stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $156.88, for a total transaction of $3,922,000.00. Following the completion of the sale, the director directly owned 100,743 shares of the company’s stock, valued at $15,804,561.84. The trade was a 19.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO James Bylund sold 2,191 shares of the company’s stock in a transaction dated Tuesday, November 18th. The shares were sold at an average price of $151.21, for a total value of $331,301.11. Following the completion of the sale, the chief operating officer owned 21,520 shares of the company’s stock, valued at $3,254,039.20. This represents a 9.24% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 49,382 shares of company stock worth $7,676,802 over the last 90 days. 1.20% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Rhenman & Partners Asset Management AB boosted its stake in shares of Repligen by 333.3% in the 2nd quarter. Rhenman & Partners Asset Management AB now owns 19,500 shares of the biotechnology company’s stock valued at $2,425,000 after purchasing an additional 15,000 shares during the last quarter. Harvest Fund Management Co. Ltd bought a new position in Repligen in the first quarter valued at approximately $132,000. XTX Topco Ltd grew its holdings in Repligen by 34.2% during the 1st quarter. XTX Topco Ltd now owns 12,935 shares of the biotechnology company’s stock worth $1,646,000 after acquiring an additional 3,295 shares during the period. Congress Asset Management Co. grew its holdings in Repligen by 18.0% during the 2nd quarter. Congress Asset Management Co. now owns 152,450 shares of the biotechnology company’s stock worth $18,962,000 after acquiring an additional 23,231 shares during the period. Finally, Dynamic Technology Lab Private Ltd raised its position in shares of Repligen by 233.6% during the 1st quarter. Dynamic Technology Lab Private Ltd now owns 9,208 shares of the biotechnology company’s stock valued at $1,172,000 after acquiring an additional 6,448 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan’s 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027.

McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan’s 9th Congressional District. She declared candidacy for the 2026 election.

Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor’s degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.